DK0853487T3 - Neutraliserende monoklonale antistoffer mod respiratorisk syncytial virus - Google Patents

Neutraliserende monoklonale antistoffer mod respiratorisk syncytial virus

Info

Publication number
DK0853487T3
DK0853487T3 DK96933810T DK96933810T DK0853487T3 DK 0853487 T3 DK0853487 T3 DK 0853487T3 DK 96933810 T DK96933810 T DK 96933810T DK 96933810 T DK96933810 T DK 96933810T DK 0853487 T3 DK0853487 T3 DK 0853487T3
Authority
DK
Denmark
Prior art keywords
antibodies
respiratory syncytial
syncytial virus
monoclonal antibodies
antibodies against
Prior art date
Application number
DK96933810T
Other languages
Danish (da)
English (en)
Inventor
Glenn R Pilkington
Page S Gilmour
Robert M Chanock
James E Crowe Jr
Brian R Murphy
Original Assignee
Us Health
Intracel Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Intracel Corp filed Critical Us Health
Application granted granted Critical
Publication of DK0853487T3 publication Critical patent/DK0853487T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1006—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against or targeting material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK96933810T 1995-09-18 1996-09-18 Neutraliserende monoklonale antistoffer mod respiratorisk syncytial virus DK0853487T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US393195P 1995-09-18 1995-09-18
PCT/US1996/014937 WO1997010846A1 (fr) 1995-09-18 1996-09-18 Anticorps monoclonaux neutralisants diriges contre le virus syncytial respiratoire

Publications (1)

Publication Number Publication Date
DK0853487T3 true DK0853487T3 (da) 2000-10-23

Family

ID=21708285

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96933810T DK0853487T3 (da) 1995-09-18 1996-09-18 Neutraliserende monoklonale antistoffer mod respiratorisk syncytial virus

Country Status (11)

Country Link
US (3) US7488477B2 (fr)
EP (2) EP0851924A1 (fr)
AT (1) ATE194291T1 (fr)
AU (2) AU7075496A (fr)
CA (2) CA2230116A1 (fr)
DE (1) DE69609188T2 (fr)
DK (1) DK0853487T3 (fr)
ES (1) ES2148799T3 (fr)
GR (1) GR3034349T3 (fr)
PT (1) PT853487E (fr)
WO (2) WO1997011177A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE474854T1 (de) * 2000-01-27 2010-08-15 Medimmune Llc Rsv neutralisierende antikörper mit sehr hohen affinität
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
CA2401652A1 (fr) * 2000-03-01 2001-09-07 Medimmune, Inc. Anticorps de recombinaison hautement efficaces et procede de production de ceux-ci
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
CA2505316C (fr) 2002-11-08 2014-08-05 Ablynx N.V. Anticorps a domaine unique diriges contre le facteur de necrose tumorale alpha et leurs utilisations
GB2398783A (en) * 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
GB0306618D0 (en) * 2003-03-22 2003-04-30 Univ Newcastle Antibody
US20100111856A1 (en) * 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
BRPI0516284A (pt) * 2004-09-23 2008-09-02 Genentech Inc anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto
US20060115485A1 (en) * 2004-10-29 2006-06-01 Medimmune, Inc. Methods of preventing and treating RSV infections and related conditions
CA2678628A1 (fr) 2007-03-06 2008-09-12 Symphogen A/S Anticorps recombinants pour le traitement des infections au virus respiratoire syncytial
EP1997830A1 (fr) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. Molécules à liaison spécifiques RSV et leur moyen de fabrication
EP2201040A1 (fr) * 2007-09-24 2010-06-30 Vanderbilt University Anticorps monoclonaux au virus respiratoire syncytial et leurs utilisations
WO2009052249A1 (fr) * 2007-10-19 2009-04-23 Genentech, Inc. Anticorps anti-tenb2 modifiés par des cystéines et conjugués anticorps-médicament
KR100938998B1 (ko) * 2008-01-08 2010-01-28 (주) 에이프로젠 호흡기 신시티움 바이러스에 대한 항체
US8591961B2 (en) 2008-09-04 2013-11-26 Allergan, Inc. Aesthetic treatment of scars and aging skin
MX2012001882A (es) 2009-08-13 2012-04-11 Crucell Holland Bv Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
KR101839163B1 (ko) 2010-06-08 2018-03-15 제넨테크, 인크. 시스테인 조작된 항체 및 접합체
CN103097412B (zh) 2010-07-09 2016-08-10 克鲁塞尔荷兰公司 抗人呼吸道合胞病毒(rsv)抗体以及使用方法
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
CN107108724A (zh) 2014-09-12 2017-08-29 豪夫迈·罗氏有限公司 半胱氨酸改造抗体和缀合物
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
EA039222B1 (ru) * 2016-07-27 2021-12-20 Мерк Шарп И Доум Корп. Антитело, нейтрализующее респираторно-синцитиальный вирус человека
WO2018075378A1 (fr) * 2016-10-17 2018-04-26 Vanderbilt University Anticorps contre le virus respiratoire syncytial humain et leurs méthodes d'utilisation
US11485775B2 (en) 2016-10-21 2022-11-01 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
US11479600B2 (en) 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
BR112019008063A2 (pt) 2016-10-21 2019-07-02 Adimab Llc anticorpos contra o vírus sincicial anti-respiratório e métodos de sua geração e uso
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CA3060581A1 (fr) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
BR112020015588A2 (pt) * 2018-01-31 2021-01-05 The Wistar Institute Of Anatomy And Biology Molécula de ácido nucleico codificando um ou mais anticorpos sintéticos, composição, anticorpo monoclonal anti-rsv, método para prevenir ou tratar uma doença, e, formulação.
WO2021202463A1 (fr) 2020-03-30 2021-10-07 Danisco Us Inc Anticorps anti-rsv

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4800078A (en) * 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
GB9019812D0 (en) * 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
GB9207479D0 (en) * 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
ES2191016T3 (es) * 1992-09-16 2003-09-01 Scripps Research Inst Anticuerpos monoclonales neutralizantes humanos para el virus respiratorio sincitial.
AU3660893A (en) * 1993-01-29 1994-08-15 Med Immune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
CA2168349A1 (fr) * 1993-07-30 1995-02-09 Lingxun Duan Immunisation intracellulaire
AU689489B2 (en) * 1993-07-30 1998-04-02 Oravax, Inc Monoclonal IgA antibody against respiratory syncytial virus

Also Published As

Publication number Publication date
GR3034349T3 (en) 2000-12-29
EP0853487A1 (fr) 1998-07-22
WO1997011177A1 (fr) 1997-03-27
US20120087909A1 (en) 2012-04-12
PT853487E (pt) 2000-11-30
US20040005324A1 (en) 2004-01-08
CA2230116A1 (fr) 1997-03-27
ATE194291T1 (de) 2000-07-15
US20090110684A1 (en) 2009-04-30
EP0851924A1 (fr) 1998-07-08
WO1997010846A1 (fr) 1997-03-27
US8221759B2 (en) 2012-07-17
DE69609188T2 (de) 2000-12-21
CA2230127A1 (fr) 1997-03-27
EP0853487B1 (fr) 2000-07-05
AU7075496A (en) 1997-04-09
AU7240096A (en) 1997-04-09
US7488477B2 (en) 2009-02-10
DE69609188D1 (de) 2000-08-10
ES2148799T3 (es) 2000-10-16

Similar Documents

Publication Publication Date Title
DK0853487T3 (da) Neutraliserende monoklonale antistoffer mod respiratorisk syncytial virus
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
WO2005056600A3 (fr) Anticorps monoclonaux se liant ou neutralisant le virus de la dengue
YU36096A (sh) Neutrališuća visoko afinitivna humana monoklonalna antitela specifična u rsv f-protein i postupci za njihovu proizvodnju
DK0671927T3 (da) Neutraliserende humane monoklonale antistoffer mod respiratorisk syncytialvirus
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
RS20100555A (en) HUMAN ANTI-NGF NEUTRAL ANTIBODIES AS SELECTIVE NGF SIGNAL ROUTE INHIBITORS
UA87093C2 (ru) ГУМАНИЗИРОВАННЫЙ ИММУНОГЛОБУЛИН, КОТОРЫЙ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С БЕТА-АМИЛОИДНЫМ ПЕПТИДОМ (Аβ)
HUP0302128A2 (hu) Anti-duális-integrin ellenanyagok, készítmények, eljárások és alkalmazások
BR9608615A (pt) Vacinas de vírus sincicial respiratório de ácido nucléico
WO2003092630A3 (fr) Identification d'anticorps monoclonaux humains largement neutralisants a reaction croisee au moyen d'un procede d'adherence sequentielle sur plaque d'antigenes de banques de presentation du phage
BR0211296A (pt) Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado
AU5328299A (en) Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine
ATE203413T1 (de) IMPFSTOFFE BESTEHEND AUS PROTEIN- ODER PEPTID- ßCOCHLEATENß UND DEREN VERWENDUNG ZUR IMMUNISIERUNG
EP1433792A3 (fr) Protéines réceptrices humaines, réactifs et méthodes associés
ATE353337T1 (de) Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet
AU4897096A (en) Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen
King et al. The use of monoclonal antibodies specific for seal immunoglobulins in an enzyme-linked immunosorbent assay to detect canine distemper virus-specific immunoglobulin in seal plasma samples
PT914417E (pt) Dnase ii humana
WO2002085924A3 (fr) Anticorps monoclonaux anti-$g(a)3(iv)nc1 et modele animal de la glomerulonephrite auto-immune humaine
ES2092960A1 (es) Gen de la proteina 1 de union a transferrina (tbp1) de actinobacillus pleuropneumoniae, utilizacion de esta en la preparacion de productos para la vacunacion contra la pleuroneumonia y en reactivos de diagnostico.
KR950701683A (ko) 클로스트리디움 퍼프린겐스 백신(Clostridium perfringens wvaccines)
TW200500465A (en) Novel humanized anti-vap-1 monoclonal antibody